Dynamics of clinical and laboratory parameters in patients with malignant ovarian neoplasms undergoing anticancer therapy
Introduction. Patients with malignant ovarian neoplasms (MON) undergoing chemotherapy (CT) are at risk of developing cancer therapy-related cardiovascular toxicity (CTR-CVT). Objective: To analyze clinical and laboratory parameters and evaluate the dynamics of CVR and CAT risk in patients with MON against the background of antineoplastic therapy. Material and methods. The prospective observational study included 63 patients with diagnosed MON who are planned to receive CT. All patients underwent CVR and CTR-CVT risk stratification, comprehensive cardiological examination before treatment initiation (Visit 1) and during follow-up (after 3 months, Visit 2), including echocardiography with global longitudinal strain (GLS) assessment of the left ventricle, 24-hour ECG monitoring, determination of troponin I and NT-proBNP levels, and lipid profile. Results. The high prevalence of patients with stage III–IV disease (n = 49; 77.8%) and high CVR (n = 34; 54%) was noted. About half of the patients had concomitant cardiovascular pathology (n = 28; 44.4%). The high and very high risks of CTR-CVT were observed in 26.9% (n = 17) of patients. Only 28% (n = 18) of patients received the necessary recommended therapy due to cardiovascular risk and concomitant pathology, and the target levels of blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) were achieved in 40 (63.5%) and 13 (20.6%) patients, respectively. The results obtained three months after the start of chemotherapy, combined with prescribed cardioprotective therapy, showed a statistically significant reduction in total cholesterol and LDL-C (p <0.05) and the improvement in target blood pressure (82.1% vs. 64.3%). None of the observed patients experienced overt cardiovascular toxicity. Conclusion. Early risk stratification, comprehensive cardiological monitoring, and timely prescription of cardioprotective therapy enable to control lipid metabolism parameters and may contribute to the prevention of cardiovascular complications in patients with ovarian cancer undergoing CT.E.N. Knyazeva, E.I. Tarlovskaya, N.A. Kamardina
Keywords
References
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
PMID: 38572751. https://doi.org/10.3322/caac.21834
- Florido R, Daya NR, Ndumele CE, Koton S, Russell SD, Prizment A, et al. Cardiovascular disease risk among cancer survivors: The Atherosclerosis Risk In Communities (ARIC) study. J Am Coll Cardiol. 2022;80(1):22–32.
PMID: 35772913. PMCID: PMC9638987. https://doi.org/10.1016/j.jacc.2022.04.042
- Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–14.
PMID: 26976915. PMCID: PMC4800750. https://doi.org/10.1161/CIRCULATIONAHA.115.020406
- Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: Comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med. 2003;17(6):481–88.
PMID: 14575384. https://doi.org/10.1007/BF03006439
- Тюляндина А.С., Коломиец Л.А., Морхов К.Ю., Нечушкина В.М., Покатаев И.А., Румянцев А.А. с соавт. Рак яичников, первичный рак брюшины и рак маточных труб. Злокачественные опухоли. 2023;13(3S2–1):201–215. [Tyulandina AS, Kolomiets LA, Morkhov KYu, Nechushkina VM, Pokataev IA, Rumyantsev AA, et al. Ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. Zlokachestvennyye opukholi = Malignant Tumors. 2023;13(3S2–1):201–215 (In Russ.)].
EDN: RWCHEA. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-201-215
- Виценя М.В., Агеев Ф.Т., Гиляров М.Ю., Овчинников А.Г., Орлова Р.В., Полтавская М.Г. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли. 2021;11(3S2–2):78–98. [Vitsenya MV, Ageev FT, Gilyarov MYu, Ovchinnikov AG, Orlova RV, Poltavskaya MG. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. Zlokachestvennyye opukholi = Malignant Tumors. 2021;11(3S2–2):78–98 (In Russ.)].
EDN: BPOXJT. https://doi.org/10.18027/2224-5057-2021-11-3s2-41
- Саевец В.В., Шаманова А.Ю., Мухин А.А., Ярина Л.В., Таратонов А.В., Власова В.М. Подходы к терапии рака яичников вчера, сегодня, завтра. Онкология. Журнал им. П.А. Герцена. 2023;12(4):67–73. [Saevets VV, Shamanova AYu, Mukhin AA, Yarina LV, Taratonov AV, Vlasova VM. Approaches to therapy for ovarian cancer yesterday, today, tomorrow. Zhurnal imeni P.A. Gertsena = P.A. Herzen Journal of Oncology. 2023;12(4):67–73 (In Russ.)].
EDN: BLPHMW. https://doi.org/10.17116/onkolog20231204167
- Трошина А.А., Андреев М.А., Стойко Ю.М., Максименков А.В. «Смертельная» коморбидность – сердечно-сосудистые заболевания и онкология: общие патогенетические аспекты (часть I). Лечебное дело. 2023;(1):6–11. [Troshina AA, Andreev MA, Stoiko YuM, Maksimenkov AV. Cardiovascular diseases and cancer: A fatal comorbidity. Common pathogenic aspects (part I). Lechebnoe delo = Medical Practice. 2023;(1):6–11 (In Russ.)].
EDN: BITHTD. https://doi.org/10.24412/2071-5315-2023-12948
- Танделов Р.К., Сельчук В.Ю., Морхов К.Ю., Нечушкина В.М., Кузнецов В.В. Роль циторедуктивных операций в лечении распространенного рака яичников (обзор литературы). Современная онкология. 2018;20(1):5–10. [Tandelov RK, Selchuk VYu, Morkhov KYu, Nechushkina VM, Kuznetsov VV. The role of cytoreduction surgery in advanced ovarian cancer (review). Sovremennaya onkologiya = Journal of Modern Oncology. 2018;20(1):5–10 (In Russ.)]. EDN: XNYCSL.
- Чазова И.Е., Ощепкова Е.В., Канторова А.Ю. Коморбидность сердечно-сосудистых и онкологических заболеваний: проблемы диагностики кардиотоксических эффектов химио- и лучевой терапии. Терапевтический архив. 2015;87(9):4–10. [Chazova IE, Oschepkova EV, Kantorova AYu. Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy. Terapevticheskiy arkhiv = Therapeutic Archive. 2015;87(9):4–10 (In Russ.)].
EDN: VINTBH. https://doi.org/10.17116/terarkh20158794-10
- Самодуров С.И., Фокин А.А., Важенин А.В., Кузнецова А.И., Курченкова О.В., Харламова У.В. Актуальные проблемы сердечно-сосудистой коморбидности среди пациентов онкологического профиля. Непрерывное медицинское образование и наука. 2025;20(2):3–7. [Samodurov SI, Fokin AA, Vazhenin AV, Kuznetsova AI, Kurchenkova OV, Kharlamova UV. Current challenges of cardiovascular comorbidity among cancer patients. Nepreryvnoye meditsinskoye obrazovaniye i nauka = Continuing Medical Education and Science. 2025;20(2):3–7 (In Russ.)]. EDN: SBGVUI.
- Васюк Ю.А., Гендлин Г.Е., Емелина Е.И., Шупенина Е.Ю., Баллюзек М.Ф., Баринова И.В. с соавт. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):152–233. [Vasyuk YuA, Gendlin GE, Emelina EI, Shupenina EYu, Ballyuzek MF, Barinova IV, et al. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021;26(9):152–233 (In Russ.)].
EDN: GZXWWW. https://doi.org/10.15829/1560-4071-2021-4703
- Тюляндин С.А., Коломиец Л.А., Морхов К.Ю., Нечушкина В.М., Покатаев И.А., Румянцев А.А. с соавт. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Злокачественные опухоли. 2020;10(3S2–1):183–195. [Tyulandin SA, Kolomiets LA, Morkhov KYu, Nechushkina VM, Pokataev IA, Rumyantsev AA, et al. Practical recommendations for the drug treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Zlokachestvennyye opukholi = Malignant Tumors. 2020;10(3S2–1):183–195 (In Russ.)].
EDN: IDDYCU. https://doi.org/10.18027/2224-5057-2020-10-3s2-10
- Саевец В.В., Привалов А.В., Важенин А.В., Семенов Ю.А., Шмидт А.В. Лечение распространенных форм рака яичников с применением комбинации внутрибрюшной химиотерапии. Уральский медицинский журнал. 2021;20(2):28–35. [Saevets VV, Privalov AV, Vazhenin AV, Semenov YA, Shmidt AV. Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy. Ural’skiy meditsinskiy zhurnal = Ural Medical Journal. 2021;20(2):28–35 (In Russ.)].
EDN: GRILAZ. https://doi.org/10.52420/2071-5943-2021-20-2-28-35
- MacFawn IP, Magnon G, Gorecki G, Kunning S, Rashid R, Kaiza ME, et al. The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions. Cancer Cell. 2024;42(11):1864–81.
PMID: 39393357. PMCID: PMC12236807. https://doi.org/10.1016/j.ccell.2024.09.007
- Каприн А.Д., Мацкеплишвили С.Т., Потиевская В.И., Поповкина О.Е., Болотина Л.В., Шкляева А.В., Полуэктова М.В. Сердечно-сосудистые заболевания у онкологических пациентов. Онкология. Журнал им. П.А. Герцена. 2019;8(2):139–147. [Kaprin AD, Matskeplishvili ST, Potievskaya VI, Popovkina OE, Bolotina LV, Shklyaeva AV, Poluektova MV. Cardiovascular diseases in cancer patients. Onkologiya. Zhurnal imeni P.A. Gertsena = P.A. Herzen Journal of Oncology. 2019;8(2):139–147 (In Russ.)].
EDN: HKVLOG. https://doi.org/10.17116/onkolog20198021139
- Когония Л.М., Русанов М.О., Шикина В.Е. Кардиотоксичность противоопухолевых препаратов и лучевой терапии у пациентов со злокачественными заболеваниями крови и сóлидными злокачественными новообразованиями. Онкогематология. 2022;17(3):127–136. [Kogoniya LM, Rusanov MO, Shikina VE. Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors Onkogematologiya = Oncohematology. 2022;17(3):127–36. (In Russ.)].
EDN: EICLZO. https://doi.org/10.17650/1818-8346-2022-17-3-127-136
- Zheng Z, Zhao Y, Xie J, Gao M, Wang Y, Li X. Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: A retrospective study. Front Pharmacol. 2024;15:1463026.
PMID: 39525635. PMCID: PMC11543948. https://doi.org/10.3389/fphar.2024.1463026
About the Authors
Ekaterina N. Knyazeva, MD, postgraduate student of the Department of internal medicine and cardiology, Privolzhsky Research Medical University; cardiologist at Nizhny Novgorod Regional Clinical Oncology Dispensary, Nizhny Novgorod, Russian Federation.E-mail: zagorodnova_kate@mail.ru
ORCID: https://orcid.org/0009-0001-5828-2966
Ekaterina I. Tarlovskaya, MD, Dr. Sci. (Medicine), professor, head of the Department of internal medicine and cardiology, Privolzhsky Research Medical University, Nizhny Novgorod, Russian Federation.
E-mail: etarlovskaya@mail.ru
ORCID: https://orcid.org/0000-0002-9659-7010.
Nadezhda A. Kamardina, MD, assistant at the Department of internal medicine and cardiology, Privolzhsky Research Medical University, Nizhny Novgorod, Russian Federation.
E-mail: n.camardina@yandex.ru
ORCID: https://orcid.org/0009-0003-9843-8536



